SWX:LEON
SWX:LEONCapital Markets

European Stocks Possibly Trading Below Estimated Value In December 2025

As the European market navigates mixed performances, with Germany's DAX seeing gains while France's CAC 40 and the UK's FTSE 100 experienced declines, investors are keenly observing economic indicators and central bank policies for cues on future movements. In this climate, identifying stocks that may be trading below their estimated value can offer potential opportunities for those looking to capitalize on market inefficiencies.
SWX:KNIN
SWX:KNINShipping

Is Kuehne and Nagel Fairly Priced After Recent 13.4% Share Price Rebound?

Wondering if Kuehne + Nagel International is quietly turning into a value opportunity, or if the recent interest is just noise? Let us unpack what the current share price is really telling you. After a rough stretch that still leaves the stock down 15.3% year to date and 10.5% over the last year, the shares have bounced with gains of 6.5% in the last week and 13.4% over the past month. Those moves come as investors refocus on global trade normalising, ongoing supply chain recalibration after...
SWX:PGHN
SWX:PGHNCapital Markets

Is Partners Group’s New AuM Data and 2026 Outlook Briefing Altering The Investment Case For Partners Group Holding (SWX:PGHN)?

Partners Group recently reported its Assets under Management as of 31 December 2025 and confirmed it will host a 2025 Business Update and 2026 Outlook presentation on 14 January 2026, offering fresh detail on its operations and plans. This combination of an AuM disclosure and upcoming outlook briefing gives investors a clearer window into how the firm is positioning its private-markets platform for the next phase of growth and product development. We’ll now explore how the latest AuM...
SWX:ALC
SWX:ALCMedical Equipment

Is Alcon Becoming a Bargain After Product Expansion and a 17.2% Year to Date Slide?

If you have been wondering whether Alcon is quietly turning into a bargain or just a value trap, you are not alone. This article is going to unpack what the current share price is really implying. The stock has slipped about 1.6% over the last week but is still up 2.5% over the past month, while longer term returns of about 2.1% over three years and 13.8% over five years show a much slower burn than many investors hoped for after a year to date drop of 17.2% and a 16.1% slide over the last...
SWX:ROG
SWX:ROGPharmaceuticals

Roche (SWX:ROG) Valuation After FDA Expansion of PATHWAY and VENTANA HER2 Diagnostic Test Uses

Roche Holding (SWX:ROG) just picked up an FDA win for expanded use of its PATHWAY anti HER2 and VENTANA HER2 tests, widening the pool of metastatic breast cancer patients eligible for ENHERTU based on more granular HER2 profiling. See our latest analysis for Roche Holding. That FDA nod slots into a busy few weeks for Roche, with new oncology and diagnostics data out of major conferences and fresh European approvals helping underpin a roughly 24.6% 3 month share price return and 29.8% 1 year...
SWX:GIVN
SWX:GIVNChemicals

Givaudan (SWX:GIVN): Reassessing Valuation After Cautious Outlook and Softer Q4 Performance

Givaudan (SWX:GIVN) is back in focus after its shares slid more than 5% when management stopped short of reaffirming full year sales growth guidance and flagged tougher market conditions alongside softer than expected Q4 growth. See our latest analysis for Givaudan. That cautious tone has landed on a stock that was already under pressure, with a 1 month share price return of minus 9.63% and a 1 year total shareholder return of minus 22.53%, even though the 3 year total shareholder return is...
SWX:BCHN
SWX:BCHNMachinery

European Dividend Stocks To Enhance Your Income Portfolio

As the pan-European STOXX Europe 600 Index experienced a slight decline, with mixed performances across major stock indexes such as Germany's DAX and France's CAC 40, investors are closely watching the European Central Bank's potential policy moves amid resilient economic indicators. In this environment of cautious optimism and potential rate hikes, dividend stocks can offer a reliable income stream for investors seeking stability and growth in their portfolios.
SWX:HOLN
SWX:HOLNBasic Materials

Holcim (SWX:HOLN) Valuation Check After CDP A-List Recognition and Deutsche Bank ‘Top Pick’ Call

Holcim (SWX:HOLN) is back in the spotlight after landing yet another spot on CDP’s A List for climate and water, while also being tagged a top pick by Deutsche Bank. See our latest analysis for Holcim. Against that backdrop, Holcim’s 9.73% 90 day share price return and 70.34% one year total shareholder return suggest momentum is building again, even after a weaker year to date share price. If Holcim’s circular construction push has you thinking about the broader opportunity set, this could be...
SWX:SPSN
SWX:SPSNReal Estate

Swiss Prime Site (SWX:SPSN): Valuation Check After Fully Deploying CHF 300m Into Yield-Accretive Zurich Offices

Swiss Prime Site (SWX:SPSN) has just wrapped up its CHF 300 million growth push by buying a fully let, modern office property in Zurich West, locking in a 4% net yield with SIX Group as tenant. See our latest analysis for Swiss Prime Site. This latest Zurich West deal lands as the share price sits at CHF 117.9 and builds on solid momentum, with an 18.8% year to date share price return and a strong 3 year total shareholder return of 68.5%. This suggests investors are steadily rewarding the...
SWX:UHR
SWX:UHRLuxury

EU Antitrust Probe Into Online Watch Pricing Could Be A Game Changer For Swatch Group (SWX:UHR)

Italian competition authorities have opened an antitrust investigation into Swatch Group and Japan’s Citizen Watch over allegedly imposing online retail prices and retaliating against distributors who offered discounts, potentially breaching European Union rules. The probe highlights growing regulatory attention on how global watchmakers manage online distribution and pricing power across their authorized retail networks. We will now examine how this antitrust scrutiny of Swatch Group’s...
SWX:UBSG
SWX:UBSGCapital Markets

Why UBS Group (SWX:UBSG) Is Up 5.4% After Proposed Easing Of Swiss Capital Rules

In recent days, Swiss lawmakers proposed a compromise to ease some of the post–Credit Suisse capital requirements for UBS, including allowing the bank to count Additional Tier 1 instruments toward foreign-subsidiary capital needs and introducing a cap on investment banking risk. This regulatory shift could materially influence how UBS allocates capital between safety buffers, growth initiatives, and shareholder distributions, with longer-term consequences for its global competitiveness and...
SWX:SREN
SWX:SRENInsurance

Swiss Re (SWX:SREN): Reassessing Valuation After New 2025–2026 Net Income Targets

Swiss Re (SWX:SREN) has provided medium-term guidance, targeting net income above USD 4.4 billion in 2025 and around USD 4.5 billion in 2026, giving investors clearer earnings visibility. See our latest analysis for Swiss Re. The guidance lands after a busy stretch for Swiss Re, with leadership changes and shifting sentiment around reinsurance risk. The stock’s 30 day share price return of minus 14.33 percent contrasts with its robust five year total shareholder return of 112.19 percent,...